Fabrication of liposomal formulation containing paclitaxel and comparison of its toxicity with non-liposomal paclitaxel on MCF-7 breast cancer cell line

of containing and the drug were 90/6±2/35%, 49/4nm and -46/74±5/55mV, respectively. Release of the drug from the liposomal system is slow within 72 hours in normal and cancerous cell conditions. The morphology of the nanoparticles was smooth and spherical, and no chemical interaction was observed between the drug and the nano-carrier. Paclitaxel liposomal also had more toxicity to MCF-7 cell line breast cancer than non-liposomal drug. Conclusion: Based on the results, the liposomal formulation of this study can be recommended for further research in breast cancer with respect to its physicochemical properties.